Insider Buying: The Oncology Institute, Inc. (NASDAQ:TOI) Director Acquires 90,562 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala acquired 90,562 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $1.04 per share, with a total value of $94,184.48. Following the completion of the purchase, the director now owns 224,971 shares in the company, valued at approximately $233,969.84. This trade represents a 67.38 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Oncology Institute Trading Up 2.7 %

Shares of Oncology Institute stock opened at $1.14 on Monday. The Oncology Institute, Inc. has a 1 year low of $0.13 and a 1 year high of $1.63. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The stock has a market cap of $86.14 million, a PE ratio of -1.46 and a beta of 0.41. The firm has a fifty day moving average price of $0.86 and a 200 day moving average price of $0.48.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $100.27 million during the quarter, compared to analyst estimates of $109.15 million. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%.

Institutional Investors Weigh In On Oncology Institute

Hedge funds have recently bought and sold shares of the stock. FreeGulliver LLC increased its holdings in shares of Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after purchasing an additional 412,578 shares in the last quarter. Tiff Advisory Services LLC increased its holdings in Oncology Institute by 13.2% in the fourth quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock valued at $921,000 after buying an additional 346,256 shares in the last quarter. Virtu Financial LLC purchased a new position in Oncology Institute in the fourth quarter valued at $41,000. Jane Street Group LLC raised its position in shares of Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after acquiring an additional 109,769 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.